認知症診療ガイドライン2017_100_第1章.indd
|
|
|
- きょうすけ さくいし
- 7 years ago
- Views:
Transcription
1 1 CQ ICD 10 /Alzheimer National Institute on Aging Alz heimer s Association workgroup NIA AA 5 DSM 5 ICD NIA AA 2011 Alzheimer 2 2 DSM neurocognitive disorders dementia major neurocognitive disorder DSM ICD G G2 G1 G G4 G1 6 ICD
2 1CQ NIA AA a b c d e McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer s disease recommendations from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement DSM 5 DSM A B C D DSM World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva World Health Organization McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer s disease recommenda tions from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM 5. Arlington, VA American Psychiatric Association PubMed #1 "Dementia/diagnosis" Majr OR "Dementia/classification" Majr OR dementia TI AND definition* TIAB OR criteria TIAB OR concept* TIAB OR "Cognition Disorders/diagnosis" Majr OR "Cognition Disorders/ classification" Majr OR cognition disorder* TI OR "cognitive dysfunction" TI AND definition* TIAB OR criteria TIAB OR concept* TIAB #1 /MTH OR /TI OR /MTH OR /TI AND SH,,, X,, OR /TH OR /TI AND /TI OR /TIOR /TI OR /TI OR /TI OR /TI OR /TI OR /TI OR /TI OR /TI 3
3 CQ 1 2 DSM 5 major neurocognitive disorder DSM 5 mild neurocognitive disorderdsm 5 subjective cognitive impairment SCI subjective cognitive decline SCD National Institute on Aging Alzheimer s Association workgroup NIA AAAlzheimer preclinical Alzheimer s disease 1 Alzheimer MCI due to Alzheimer s disease 2 Alzheimer Alzheimer s disease dementia Alzheimer 3 3 stage 1stage 2 stage 3 DSM neurocognitive disorders delirium major neurocognitive disorder DSM 5 mild neurocognitive disorderdsm vascular cognitive impairment VCI vascular dementia VaD 5 VCI VaD cerebral autosomal dominant arteriop athy with subcortical infarcts and leukoencephalopathy CADASIL cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy CARASIL Binswanger Alzheimer VaD vascular cognitive disorder VCD CQ Petersen 7 DSM 5 NIA AA ICD CQ4B 5 age associated memory impairment AAMIaging associated cognitive decline AACDmild cognitive disorder MCDmild neurocognitive decline MNCD cognitive impairment no dementia CIND 9 1 Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer s disease recommendations 4 1
4 1CQ 1 2 from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer s disease recom mendations from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzhei mer s disease. Alzheimers Dement McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer s disease recommenda tions from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM 5. Arlington, VA American Psychiatric Association Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke Roman GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med World Health Organization. International Statistical Classification of Diseases and Related Health problems. 10th Revision. Geneva World Health Organization PubMed #1 "Dementia/diagnosis" Majr OR "Dementia/classification" Majr OR dementia TI AND definition* TIAB OR criteria TIAB OR concept* TIAB OR "Cognition Disorders/diagnosis" Majr OR "Cognition Disorders/ classification" Majr OR cognition disorder* TI OR "cognitive dysfunction" TI AND definition* TIAB OR criteria TIAB OR concept* TIAB #1 /MTH OR /TI OR /MTH OR /TI AND SH,,, X,, OR /TH OR /TI AND /TI OR /TIOR /TI OR /TI OR /TI OR /TI OR /TI OR /TI OR /TI OR /TI 5
5 CQ 1 3 DSM 5 Alzheimer Lewy HIV Parkinson Huntington 1 1 ICD 10 Alzheimer 2 DSM 5 Alzheimer Lewy HIV Parkinson Huntington 3 B 12 treatable dementia World Health Organization. International Statistical Classification of Diseases and Related Health problems. 10th Revision. Geneva World Health Organization American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM 5. Arlington, VA American Psychiatric Association PubMed #1 "Dementia/etiology" Majr OR dementia TI AND etiology OR "Cognition Disorders/etiology" Majr OR cognition disorder* TI OR "cognitive dysfunction" TI AND etiology AND "Risk Factors" Majr OR risk factor* TI #1 /MTH OR /TI OR /MTH OR /TI AND SHOR /TI or /TI 6 1
6 1CQ Alzheimer Lewy /Parkinson Huntington 2VaD VaD VaD VaD HIV AIDS Creutzfeldt Jakob 8 9 Cushing 10 Marchiafava Bignami B 1 Wernicke Korsakoff B 12 D A 5 FU B C D Wilson 11 Behçet Sjögren Fahr AND /TH OR /TI OR /TI AND PT OR SHAND /TI or / TI 7
7 CQ 1 4 Alzheimer DSM 5 1 Alzheimer Alzheimer
8 1CQ 1 4 1Alzheimer Alzheimer 2 Alzheimer Alzheimer 3 Alzheimer Alzheimer 1 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM 5. Arlington, VA American Psychiatric Association PubMed #1 "Dementia/diagnosis" Majr OR dementia TI AND diagnosis OR diagnostic OR "Cognition Disorders/ diagnosis" Majr OR cognition disorder* TI OR "cognitive dysfunction" TIAND diagnosis OR diagnostic AND "Diagnosis, Differential" Majr OR "Diagnostic Errors" Mesh OR "differential diagnosis" TI OR diagnostic error* TI OR misdiagnosis TI #1 /MTH OR /TI OR /MTH OR /TI AND SH,,, X,, OR /TH OR /TI AND /MTH OR /TI OR /MTH OR /TI OR /TI 9
9 CQ % A % % 1 2, % CI % %CI , , , [%] ~69 70~74 75~79 80~84 85~89 90~94 95~[ 歳 ] 男性女性全体
10 1CQ 1 5 [100 万人 ] [ 年 ] 2 Alzheimer s Disease International. World Alzheimer Report 2015 The Global Impact of Dementia an analysis of prevalence, incidence, cost and trends. London Alzheimer s Disease International 高所得国 低 ~ 中所得国 1 Dodge HH, Buracchio TJ, Fisher GG, et al. Trends in the prevalence of dementia in Japan. Int J Alzheimers Dis Ikejima C, Hisanaga A, Meguro K, et al. Multicentre population based dementia prevalence survey in Japan a preliminary report. Psychogeriatrics Alzheimer s Disease International. World Alzheimer Report 2015 The Global Impact of Dementia an analysis of preva lence, incidence, cost and trends. London Alzheimer s Disease International Matthews FE, Arthur A, Barnes LE, et al. A two decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England results of the Cognitive Function and Ageing Study I and II. Lancet Qiu C, von Strauss E, Bäckman L, et al. Twenty year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology Schrijvers EM, Verhaaren BF, Koudstaal PJ, et al. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology Doblhammer G, Fink A, Fritze T. Short term trends in dementia prevalence in Germany between the years 2007 and Alzheimers Dement Satizabal CL, Beiser A, Chêne G, et al. Temporal trends in Dementia Incidence in the Framingham Study Jul 17 Copenhagen AAIC PubMed #1 "Dementia/epidemiology" Majr OR dementia TIAND "Morbidity" Mesh OR morbidity TI OR incidence TI OR prevalence TI #1 /TH OR /TI AND /TH OR /TI OR /TI AND /TH OR /TI OR / TI OR /TI 11
11 CQ 1 6 Alzheimer B 2010 Alzheimer 67.6% 19.5% Lewy / Parkinson 4.3% Alzheimer 1990 Alzheimer 80 2 Alzheimer Alzheimer 6 Lewy 1 Alzheimer % % %
12 1CQ Dodge HH, Buracchio TJ, Fisher GG, et al. Trends in the prevalence of dementia in Japan. Int J Alzheimers Dis Wakutani Y, Kusumi M, Wada K, et al. Longitudinal changes in the prevalence of dementia in a Japanese rural area. Psychogeriatrics Sekita A, Ninomiya T, Tanizaki Y, et al. Trends in prevalence of Alzheimer s disease and vascular dementia in a Japanese community the Hisayama Study. Acta Psychiatr Scand PubMed #1 "Dementia/epidemiology" Majr OR dementia TIAND "Morbidity" Mesh OR morbidity TI OR incidence TI OR prevalence TIAND subtype TI OR subtypes TI OR "sub type" TI OR "sub types" TI #1 /TH OR /TI AND /TH OR /TI OR /TI OR /TI AND /AL 13
13 CQ 1 7 C % 1 70 HR p % HR , % p % p [%] [ 年 ] 知症者の平均余命の喪失報告年認 1 % Brodaty H, Seeher K, Gibson L. Dementia time to death a systematic litera ture review on survival time and years of life lost in people with dementia. Int Psychogeriatr
14 1CQ 1 7 % Schrijvers EM, Verhaaren BF, Koudstaal PJ, et al. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology Langa KM, Larson EB, Karlawish JH, et al. Trends in the prevalence and mortality of cognitive impairment in the United States is there evidence of a compression of cognitive morbidity? Alzheimers Dement Qiu C, von Strauss E, Bäckman L, et al. Twenty year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology Doblhammer G, Fink A, Fritze T. Short term trends in dementia prevalence in Germany between the years 2007 and Alzheimers Dement Brodaty H, Seeher K, Gibson L. Dementia time to death a systematic literature review on survival time and years of life lost in people with dementia. Int Psychogeriatr PubMed #1 "Dementia/mortality" Majr OR "Cognition Disorders/mortality" Majr OR "Dementia/epidemiology" Majr OR "Cognition Disorders/epidemiology" Majr AND "Mortality" Mesh OR mortality TIAB OR survival TIABAND "Morbidity" Mesh OR "Life Expectancy" Mesh OR "morbidity" TI OR "incidence" TI OR "prevalence" TI OR "disease duration" TI OR "dementia" TI AND "morbidity" TI OR "incidence" TI OR "prevalence" TI #1 /MTH OR /TI OR /MTH OR /TI AND /TI OR /TH OR / TI OR /TI OR /TH OR /TH OR /TI OR /TI OR /TI 15
15 CQ 1 8 Alzheimer β(aβ) 1 Alzheimer Lewy α Lewy Lewy 2 Parkinson Lewy Lewy Alzheimer 3 Pick fronto temporal lobar degeneration FTLD TDP 43 fused in sarcoma FUS 4 Pick Pick TDP 43 FTLD FTLD Aβ Alzheimer primary age related tauopathy PART 5 CA1 Alzheimer FTLD 16 1
16 1CQ chronic traumatic encephalopathy CTE 7 8 Alzheimer Alzheimer 314 CQ Braak H, Braak E. Neuropathological staging of Alzheimer related changes. Acta Neuropathol Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson s disease. Neurobiol Aging McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies third report of the DLB Consortium. Neurology Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration an update. Acta Neuropathol Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age related tauopathy PART a common pathology associated with human aging. Acta Neuropathol Brenowitz WD, Monsell SE, Schmitt FA, et al. Hippocampal sclerosis of aging is a key Alzheimer s disease mimic clini cal pathologic correlations and comparisons with both alzheimer s disease and non tauopathic frontotemporal lobar degeneration. J Alzheimers Dis McKee AC, Daneshvar DH, Alvarez VE, et al. The neuropathology of sport. Acta Neuropathol Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia an update. Nat Rev Neurol PubMed #1 "Dementia/pathology" Majr OR dementia TI AND patholog* TI OR neuropatholog* TIAND "Brain/ pathology" Majr OR "Parkinson Disease/pathology" Majr OR "Inclusion Bodies/metabolism" Mesh AND neuropathologic TI OR neuropathological TI OR pathologic TI OR "Frontotemporal Lobar Degeneration/ pathology" Mesh OR "Lewy Body Disease/pathology" Mesh OR "Alzheimer Disease/pathology" Majr OR Alzheimer* TI AND patholog* OR neuropatholog* AND "Brain/pathology" Mesh OR "Parkinson Disease/ pathology" Mesh OR "primary age related tauopathy" TIAB OR PART TI AND "pathological feature" TIAB OR "pathological process" TIAB OR "pathologic process" TIAB OR "neuropathological criteria" TIAB OR neuropathological stage* TIAB OR pathogenic mechanism* TIAB OR "Frontotemporal Lobar Degeneration/classification" Majr OR "Lewy Body Disease/physiopathology" Majr OR "Tauopathies/pathology" Majr AND "Aging/pathology" MajrOR "Athletic Injuries/pathology" Majr AND Cognition Mesh AND "Brain/pathology" Majr OR "Inclusion Bodies/metabolism" Mesh AND neuropatholog* TI OR patholog* TI OR "pathologic assessment" TIAB #1 /TH OR /TI OR Alzheimer/TI OR /TI OR Lewy /TI AND /TH OR /TI OR Parkinson /TH OR Parkinson/TI AND SH OR /TH AND /TI AND /TI OR /TI OR Alzheimer/TI OR /TI OR Lewy /TI 17
認知症治療薬の考え方，使い方
Ch a pterⅠ 1 はじめに わが国における高齢者の認知症有病率は今後も高くなり 認知症者が増 加していく可能性が示されている1,2 海外においても アジア アフリカ などを中心に今後の認知症者数が増大する可能性が指摘されている 一 方 欧米においては認知症者発症率の減少を指摘する報告もある しかし 高齢化もあって認知症者数は増加すると考えられ わが国のみならず世界 の認知症者数は増加すると考えられている
PET n = 7 AD n = 20 図 3 PiB AD A 3. わが国のアミロイド PET の現状 PET 100 PiB 15 BF 図 4 J-ADI 105 図 5 20%MCI 60% AD 90% MCI AD AD E ApoE 4 AD 4 図 6 4.
病態理解と薬剤開発におけるアミロイド PET 検査の現状 Current Status of Amyloid PET in Pathophysiological Research and Drug Development for Alzheimer s Disease 東京都健康長寿医療センター研究所附属診療所 / 所長 * 1. はじめに PET A A AD 図 1 AD AD PET 2. アミロイド
認知症診療 実践ハンドブック
Ⅰ. 認知症 軽度認知障害の診断 治療へのアプローチ 1 認知症の症候, 検査, 診断 1 認知症の症候, 検査, 診断 1 認知症 軽度認知障害の概念, 実態, 診断への道筋 A 認知症 軽度認知障害とは? 1. 認知症の概念と診断基準認知症とは一度正常に発達した認知機能が後天的な脳の障害によって持続的に低下し, 日常生活や社会生活に支障をきたすようになった状態を指す. 診断基準として, 世界保健機関による国際疾病分類第
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
資金源及び利益相反 (conflict of interest:coi) 本ガイドライン作成に必要な資金は 日本神経学会の負担で行った 委員会開催の会議室経費や委員会出席のための交通費などの費用を負担し 原稿作成や会議参加などについての委員 研究協力者への報酬は支給しなかった 一般社団法人日本神経学
認知症疾患診療ガイドライン 2017 の序に替えて ( 案 ) 日本神経学会認知症疾患診療ガイドライン作成委員会委員長 中島健二 2002 年に 痴呆疾患治療ガイドライン が公開され 2010 年に日本神経学会 日本神経治療学会 日本精神神経学会 日本認知症学会 日本老年医学会 日本老年精神医学会の 6 学会が協力して合同で clinical question(cq) を用いた 認知症疾患治療ガイドライン
若年認知症支援ハンドブック_H19
64 18 18 19 203 50 65 1) - 1 - 18 64 40 64 65 18 3064 10 54 4564 98 35 15 18 2) 45 64 10 6781 3) 1996 10 32 25600 34 10 70008000 4, 5) 10 5) 30 5 2 2) 58 42 2) 2:1 4) - 2 - 1 24, 6) Harvey 3064 185
認知症診療ガイドライン2017_200_第2章.indd
2 behavioral and psychological symptoms of dementia BPSD BPSD BPSD 18 2 2 1,2 1 CQ 2 1 1. 2. frontotemporal lobar degeneration FTLD 3. 3 a. CQ 2 1 19 1 1 Alzheimer Lewy Alzheimer Alzheimer Lewy Alzheimer
[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]
![[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]](/thumbs/93/113784833.jpg "[4], [5] [6] [7] [7], [8] [9] 70 [3] 85 40% [10] Snowdon 50 [5] Kemper [3] 2.2 [11], [12], [13] [14] [15] [16]")
1,a) 1 2 1 12 1 2Type Token 2 1 2 1. 2013 25.1% *1 2012 8 2010 II *2 *3 280 2025 323 65 9.3% *4 10 18 64 47.6 1 Center for the Promotion of Interdisciplinary Education and Research, Kyoto University 2
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
1) University Group Diabetes Program: A study of hypoglycemic agents on vascular complica- in patients with adult-onset tions diabetes. I. Design, methods and baseline results. Diabetes 19 (suppl. 2):
! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The
認知症診療ガイドライン2017_1400_第14章.indd
14CQ 14 1 14 CQ 14 1 vascular dementia VaD VaD WHO 10 ICD 10 5 DSM 5 Alzheimer Alzheimer s disease diagnostic and treatment center ADDTC National Institute of Neurological Disorders and Stroke NINDS Association
不安障害研究, 9(1), 17-32, 2017
9(1), 17 32, 2017 Panic and Agoraphobia Scale 1 2 3 2 2 2 2 4 4 1 2 3 4 Panic and Agoraphobia Scale PAS DSM-IV-TR APA, 2000 3 4 PAS PAS PAS Patient Global Impression Improvement PAS 1980 Diagnostic and
温泉用語解説集（HP）
Q&A WHO ICD11 Q&A 2011 3 15 EHR(Electronic Health Record) (International Classification of Diseases) (International Classification of Diseases)WHO(World Health Organization) ICD11 ICD11 Hierarchy-Parents
本文／宮川充司先生
Journal of the School of Education, Sugiyama Jogakuen University 7 65 78 2014 Article DSM-5, Revised Diagnostic Criteria by American Psychiatric Association : Neurodevelopmental Disorders, Intellectual
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Vol.0 No. 0 図 Montreal Cognitive AssessmentMoCA orientation visuospatial attention orientation 4 visuospatial executive MMSE MoCA language language me
Parkinson 病の認知機能障害を MMSE と MoCA により評価した多施設共同研究 : 慶應 PD データベース Cognitive impairment in Parkinson s disease patients evaluated by the Montreal Cognitive Assessment and the Mini-Mental State Examination.
Soundcell Method（SCM）による高齢者の認知機能評価の可能性
Soundcell Method SCM Soundcell Soundcell Method SCM Soundcell Soundcell SCM SCM SCM SCM MMSE TMT-A TMT-BSCM SCM SCM SCM MMSE MMSE SCM SCM Soundcell Soundcell Method Soundcell Soundcell Soundcell Soundcell
470 Dementia Japan Vol. 24 No. 4 December 2010 Freyne A et al., 1999, Sampson E et al., 2004 目的 方法と対象 , ,
Dementia Japan 24 : 469-478, 2010 469 原著 要旨 65 early - onset dementia : EOD EOD EOD 2,626 Epidemiology of Early - Onset Dementia in Ehime Tetsuo Kashibayashi 1,2, Tomohisa Ishikawa 3, Kenjiro Komori 2,
SHAPS YJEXPANDS 2SHAPS YJEXPANDS 2 3SHAPS YJEXPANDS 2 Depression Inventory DSM DSMR Montgomery Åsberg Depression Rating
1135 特集認知症 (AD,DLB) およびパーキンソン病における認知障害と抑うつ症状 1 2 QOL 1030 SHAPS SHAPS 索引用語 SnaithHamilton Pleasure Scale SHAPS はじめに QOL 1 Syndrome Subtype Prevalence Depression Major depression 1030 Minor depression 1020
Ⅰ診断 症候 鑑別診断 認知機能に関する訴え 正常ではなく認知症でもない 認知機能の低下あり 日常生活機能は正常 Amnestic n-amnestic 認知障害は記憶障害のみ 認知障害は１領域に限られる Amnestic Single 図1 表1 記憶障害 Amnestic Multiple n
1) 認知症 1 軽度認知障害 () とはどのような状態でしょうか? の診断基準を教えてください. 1 概要 Mild Cognitive Impairment() とは本来 Alzheimer 病 (AD) など認知症とはいえないが, 知的に正常ともいえない状態を指す. 最近ではおおよそ AD の前駆状態を意味する用語と捉える人が多い. このような状態が注目される背景には, 新治療薬開発により AD
untitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
認知症診療ガイドライン2017_800_第8章.indd
8CQ 8 frontotemporal lobar degeneration FTLD Pick Alzheimer FTLD Alzheimer FTLD frontotemporal dementia FTD FTLD FTLD FTLD behavioral variant frontotemporal dementia bvftd semantic dementia SD Sylvius
Juntendo Medical Journal
* Department of Health Science Health Sociology Section, Juntendo University School of Health and Sports Science, Chiba, Japan (WHO: Ottawa Charter for Health promotion, 1986.) (WHO: Bangkok Charter
Vol.21 No AD Japanese-ADNI J-ADNI 2015 AMED AD NA-ADNI 400 AD AD 2. NA-ADNI 研究の主な成果 NA-ADNI 2004 NA-ADNI ADNI, ADNI-GO ADNI-2 phase
アルツハイマー型認知症のバイオマーカーの現状と課題 Biochemical biomarkers for Alzheimer s disease: present status and awaiting solution 京都府立医科大学分子脳病態解析学 / 教授 * 1. はじめに 460 65 10 1 85 3 1 Alzheimer s disease AD 5 7 2500 AD 460
’lŁ¶Ÿ_‰ƒ52†\3(‡æ‡±)/2.’¼Œ{†E‘¼Œ{
6 I 1995 PTSD Posttraumatic Stress Disorder 2002 3 JSTSS II ABCC Atomic Bomb Casualty Commission RERF 1 1949 50 2 3 3 3 2 1 1951 ; 1958 7.3 1961 30 3 Encephalose Somatose 1961 ; 1963 132 28 1996 a 1959
パーソナリティ研究2006 第14巻 第2号 214–226
2006 14 2 214 226 2006 (NPI-35) 1) Raskin & Hall (1979) Emmons (1984) (Narcissistic Personality Inventory; NPI) Raskin & Terry (1988) NPI (Narcissistic Personality Inventory-35; NPI-35) 1 35 5 2 3 4 NPI-35
3) Balas. C. Michele, Happ. B. Beth, Yang. Wei et al: Outcomes associated with delirium in older patients in surgical ICUs, Chest, vol.135 (1), 18-25, 2009 4) Ban Thomas; Chronic disease and depression
高齢化とマクロ投資比率―国際パネルデータを用いた分析―
196 2017 * ** ** ** ** 160 2 2 JEL Classification Codes E21, E22, J11 Keywords * ESRI 28 ESRI 29 3 17 ESRI ** 115 196 Population Aging and Domestic Investment An Analysis Using International Panel Data
jsfm_著者紹介_160520
Sarah M. A. Caney 1 European Journal of Companion Animal Practice (2015) Autumn 25 (3) EJCAP 25(3) Special issue 2015 P4 Commissioned paper* Management of the elderly cat Sarah M. A. Caney 1-01 - EJCAP
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: , 要旨 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visi
36:378 第 38 回日本脳卒中学会講演シンポジウム 原著 36: 378 384, 2014 1 2 要旨 1999 2012 10 31 29 26 80 30 TIA 2 t-pa Key words: stroke registry, stroke subtype, onset-visit time, chronological change はじめに 4 12 23 27 1 Japan
WHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support
66-1 田中健吾・松浦紗織.pwd
Abstract The aim of this study was to investigate the characteristics of a psychological stress reaction scale for home caregivers, using Item Response Theory IRT. Participants consisted of 337 home caregivers
82 CQ2 医療機関受診時にけいれん発作が続いている場合, 最初に試みるべき治療は何か 1 PubMed #1 Status Epilepticus/therapy Majr OR status epilepticus TI AND therap TIAB OR treatment TIAB NO
81 文献検索式 CQ1 CQ14 CQ1 CQ1 けいれん発作に対して重積化を防ぐために早期に治療介入することは必要か 1 PubMed 1980 1 2015 12 2016 4 30 #1 Status Epilepticus/therapy Majr OR status epilepticus TI AND therap TIAB OR treatment TIAB OR prevent TIAB
Ⅰ. Statistics Concerning Health Birthweight (1) Birthweight by year (2) Mean birthweight by prefecture, 2007-1997 (3) Percentage of births under 2,500g by prefecture, 2007-1997 Sex Ratio (4) Sex ratio
好酸球性副鼻腔炎:診断ガイドライン（JESREC Study）
118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
PTSD PTSD DSM PTSD
PTSD PTSD PTSD PTSD PTSD Post Traumatic Stress Disorder Trauma PTSD PTSD PTSD PTSD PTSD DSM PTSD WHO World Health Organization PTSD ICD DSMICD DSM PTSD PTSD PTSD PTSD PTSD PTSD PTSD PTSD PTSD PTSD PTSD
8 8.1 Lieberman; db Kisilevsky; 1989 Hartikainen; db 90 db Ando & Hattori; 1973 Suzuki & Kabuto; ,000 2,500g 13 Lagers
8 8.1 Lieberman; 1975 100 105 db Kisilevsky; 1989 Hartikainen; 1994 78 db 90 db Ando & Hattori; 1973 Suzuki & Kabuto; 1978 713 40,000 2,500g 13 Lagerstrom et al.; 1991 Rantakallio; 1985, McDermott et al.;
＠０８４６００２５ヨコ／伊東 ２１７号
A B B A B A B A B stratification inequality Marmot, Smith, Why are the Japanese living longer?, British Medical Journal, 1989 Kondo, Kawachi, Subramanian, Takeda, Yamagata Do social comparisons
1) Delbet P: Retrocissement du choledoque. Cholecysto-duodenostomie. Bull Mem Soc Nat Chir 50: 1144-1146, 1924 2) Wiesner RH, LaRusso NF: Clinicopathologic Features of the Syndrome of Primary Sclerosing
PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
untitled
2010 58 1 39 59 c 2010 20 2009 11 30 2010 6 24 6 25 1 1953 12 2008 III 1. 5, 1961, 1970, 1975, 1982, 1992 12 2008 2008 226 0015 32 40 58 1 2010 III 2., 2009 3 #3.xx #3.1 #3.2 1 1953 2 1958 12 2008 1 2
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
JHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
02古郡氏李氏_a_4.indd
55 2014 e.g2004 2005 2001 1980 101990 1 2 2002 2003 25,000 20038,000 2013 10 2013 1,787 21.623 4,302 1 HUD portal.hud. gov/.../huddoc?id=pih2013 15.pdf... 2 14 105 30,000 25,000 25,296 20,000 15,000 10,000
<95DB8C9288E397C389C88A E696E6462>
2011 Vol.60 No.2 p.138 147 Performance of the Japanese long-term care benefit: An International comparison based on OECD health data Mie MORIKAWA[1] Takako TSUTSUI[2] [1]National Institute of Public Health,
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
日本における結婚観の変化―JGSS累積データ を用いた分析―
JGSS 2000-2010 JGSS Changes in Attitudes toward Marriage in Japan: Analyses Using the JGSS Cumulative Data 2000-2010 Sayaka K. SHINOHARA JGSS Research Center Osaka University of Commerce Using the Japanese
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
untitled
2005 10 13 Dr. RGA 19602000 10 Australian Institute of of Health and and Welfare 2004 ABS Cat. Cat. No. No. 3201.0; AIHW National Population Database 1875 2 211997 8 122164 http://www.wowzone.com/calment.htm
untitled
Quantitative Risk Assessment on the Public Health Impact of Pathogenic Vibrio parahaemolyticus in Raw Oyster 1 15 5 23 48 2 21 1 16 1 16 1 11 3 1 3 4 23 1 2 16 12 16 5 6 Hazard IdentificationExposure
202
201 Presenteeism 202 203 204 Table 1. Name Elements of Work Productivity Targeted Populations Measurement items of Presenteeism (Number of Items) Reliability Validity α α 205 α ä 206 Table 2. Factors of
I
九州大学学術情報リポジトリ Kyushu University Institutional Repository 熊本県水俣市の限界集落における耕作放棄地の拡大とその要因 寺床, 幸雄九州大学大学院人文科学府 : 博士後期課程 : 農村 農業地理学 Teratoko, Yukio http://hdl.handle.net/2324/20036 出版情報 : 地理学評論. 82 (6), pp.588-603,
untitled
13 15 16 11 12 ADHD 13 14 ADHD 13 15 ADHD ADHD 14 10 LD ADHD 15 LDADHD ADHD ADHD ADHD INDEX 1 ADHD 6 ADHD ADHD ADHD ADHDRS Achenbach TRF Werry-Weiss-Peters Children Attention Problems scale Gomez 10 11
, PDD ASD p.,.,..,..,.,..,.,..,.,.,.,, 146
Study on the System of the Chinese Autistic in Japan Xiaotong Ro abstract This study note is mainly introduced the research of China s autistic child treatment in Japan. There is not very much research
Influences of mortality from main causes of death on life expectancy. \ An observation for the past 25 years, 1950-1975, in Japan \ Takao SHIGEMATSU* and Zenji NANJO** With the Keyfitz-Nanjo method an
社会関係資本と外国人に対する寛容さに関する研究―JGSS-2008 の分析から―
JGSS-2008 Social Capital and Tolerance toward Foreigners in Japan: Analysis of JGSS-2008 Emi OOKA School of Sociology Kwansei Gakuin University The goal of this paper is to explore how tolerance towards
デフレの定義（最新版）.PDF
DP/01-1 Director General for Economic Assessment and Policy Analysis CABINET OFFICE E-mail : [email protected] 1 2 3 i (ii) 4 5 Deflation defined as at least two consecutive years of price decreases.
大学論集第42号本文.indb
42 2010 2011 3 279 295 COSO 281 COSO 1990 1 internal control 1 19962007, Internal Control Integrated Framework COSO COSO 282 42 2 2) the Committee of Sponsoring Organizations of the Treadway committee
March Attention Deficit Hyperactivity Disorder Attention Deficit Hyperactivity Disorder ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD ADHD R. ADHD ADHD Cf. ADHD ADHD LD&ADHD LD ADHD ADHD
40B: 43-54 2010 43 2010 1 27 Satoshi Shimai 1 and Shigehiro Fujimoto 2 1 Center for Liberal Arts and Education, Minami-Kyushu University, Miyakonojo,
40B: 43-54 2010 2010 1 27 Satoshi Shimai 1 and Shigehiro Fujimoto 2 1 Center for Liberal Arts and Education, Minami-Kyushu University, Miyakonojo, Miyazaki 885-0035, Japan; 2 Miyakonojo Public Health Institute,
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
08_中嶋真美.indd
56 2015 pp. 175 190 CBT CBT CBT UNWTO 2015 2013 10 2015 11 3,300 2010 2030 3.3 2030 182014 1 2,450 GDP 9 2016 1 30 175 56 UNESCO 2010 Living Heritage Cultural Landscape Community-Based Tourism 2002UNWTO